PRQRライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders...

Stats
本日の出来高	254 460
平均出来高	203 650
時価総額	160.83M
EPS	€0 ( 2024-04-03 )
次の収益日	( €-0.120 ) 2024-05-21
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-5.38
ATR14	€0.0150 (0.75%)

ボリューム相関

長: 0.38 (neutral)

短: 0.44 (neutral)

Signal:(41.843) Neutral

ProQR Therapeutics NV 相関

10 最も正の相関
ECHO	0.961
SIOX	0.958
MLVF	0.954
IIN	0.95
CDZI	0.949
EXAS	0.942
BTWN	0.94
EXFO	0.934
GDNR	0.933
BKCH	0.932

10 最も負の相関
SNPX	-0.971
UTME	-0.963
ISPO	-0.956
PDBC	-0.95
LARK	-0.944
KTTA	-0.943
RIVN	-0.937
OP	-0.936
HMNF	-0.934
PIII	-0.934

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

ProQR Therapeutics NV 相関 - 通貨/商品

0.55
( weak )

0.72
( moderate )

0.00
( neutral )

0.77
( moderate )

-0.56
( weak negative )

-0.83
( strong negative )

ProQR Therapeutics NV 財務諸表

Annual	2023
収益:	€6.38M
総利益:	€6.38M (100.00 %)
EPS:	€-0.340

FY	2023
収益:	€6.38M
総利益:	€6.38M (100.00 %)
EPS:	€-0.340

FY	2022
収益:	€4.04M
総利益:	€1.56M (38.68 %)
EPS:	€-0.910

FY	2021
収益:	€1.35M
総利益:	€0.00 (0.00 %)
EPS:	€-1.231

Financial Reports:

No articles found.

ProQR Therapeutics NV

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.